abstract Genetic, neuropathological and biochemical evidence implicates α-synuclein, a 140 amino acid presynaptic neuronal protein, in the pathogenesis of Parkinson's disease and other neurodegenerative disorders. The aggregated protein inclusions mainly containing aberrant α-synuclein are widely accepted as morphological hallmarks of α-synucleinopathies, but their composition and location vary between disorders along with neuronal networks affected. α-Synuclein exists physiologically in both soluble and membran-bound states, in unstructured and α-helical conformations, respectively, while posttranslational modifications due to proteostatic deficits are involved in β-pleated aggregation resulting in formation of typical inclusions. The physiological function of α-synuclein and its role linked to neurodegeneration, however, are incompletely understood. Soluble oligomeric, not fully fibrillar α-synuclein is thought to be neurotoxic, main targets might be the synapse, axons and glia. The effects of aberrant α-synuclein include alterations of calcium homeostasis, mitochondrial dysfunction, oxidative and nitric injuries, cytoskeletal effects, and neuroinflammation. Proteasomal dysfunction might be a common mechanism in the pathogenesis of neuronal degeneration in α-synucleinopathies. However, how α-synuclein induces neurodegeneration remains elusive as its physiological function. Genome wide association studies demonstrated the important role for genetic variants of the SNCA gene encoding α-synuclein in the etiology of Parkinson's disease, possibly through effects on oxidation, mitochondria, autophagy, and lysosomal function. The neuropathology of synucleinopathies and the role of α-synuclein as a potential biomarker are briefly summarized. Although animal models provided new insights into the pathogenesis of Parkinson disease and multiple system atrophy, most of them do not adequately reproduce the cardinal features of these disorders. Emerging evidence, in addition to synergistic interactions of α-synuclein with various pathogenic proteins, suggests that prionlike induction and seeding of α-synuclein could lead to the spread of the pathology and disease progression. Intervention in the early aggregation pathway, aberrant cellular effects, or secretion of α-synuclein might be targets for neuroprotection and disease-modifying therapy.
The synuclein protein family
AS is an illustrative member of the rapidly growing family of natively unfolded proteins that lack a typical secondary structure [14, 39] .
The synucleins are small (127) (128) (129) (130) (131) (132) (133) (134) (135) (136) (137) (138) (139) (140) from random coil to β-sheet (protofibril and fibril formation) [62] , with critical residues for its aggregation or fibrillation (residues [66] [67] [68] [69] [70] [71] [72] [73] [74] [56]; (3) a variable carboxy terminal acidic tail (residues 95-140) that appears critical for the chaperone-like activity of AS [63] (Figure 1 ).
The carboxy-terminus inhibits β-sheet and fibril formation [62, 64] . AS contains several phosphorylation sites for protein kinases [54] .
Over half of the molecule (amino acids 7-87) is composed of 7 motifs with a KTKEGV sequence, which are part of 11-residue repeats forming 5 amphipathic helices on the amino-terminal half responsible for its lipid affinity [14, 54, 63] , although this has recently been debated
[17]; helix 5 is responsible for protein-protein interactions [65] . While the hydrophobic NAC region remains dynamically disordered, the SL1 binding mode (residues 3-2) is prone to intermolecular interactions which progress toward oligomers and fibrils [66] .
The predominant physiological species of AS are a helically folded tetramer or a disordered monomer with a low propensity to aggregate into fibrils [57] [58] [59] 67] . It is potentially prone to misfold and has a strong tendency to self-aggregate in vivo [68] , resulting in toxicity [69] . Wild-type (WT) AS is monomeric and intrinsically/natively unfolded at low concentration but adopts an α-helical conformation when bound to membranes [70, 71] . AS is an intrinsically disordered protein but a very dynamic molecule that can adopt different conformational states depending on conditions and cofactors [72, 73] The misfolded isoform of the protein may lose the ability to bind membranes after the translation and accumulates as free AS in the cell.
Fibrils generated in vivo from AS show similar features characteristic of amyloid fibrils and include an antiparallel β-sheet structure [62, 77] . Recent nuclear magnetic resonance (NMR) studies of full-length AS fibrils showed that the core extends with a repeated structural motif, thus disagreeing with their previously proposed fold [78] . The secondary structure of AS is determined by its environment and implies that the conformation of endogenous AS depends upon whether it is cytoplasmic or membran-bound [79] . Rapid exchange of AS between bound and unbound states provides mechanisms to ensure that stable cellular structures remain dynamic and susceptible to regulation. Increased iron levels either directly or via ironincreased levels of oxidative stress (OS) catalyze the conversion of α-helical AS conformation into β-pleated conformation, which is found in LBs and GCIs [108, [110] [111] [112] . On the other hand, metal-catalyzed oxidation of AS inhibits formation of filaments with increased formation of β-sheet rich oligomers or protofibrils [113] .
Advanced glycation endproducts (AGEP) and iron interact with AS aggregation [114, 115] , which is further promoted by increased calcium [116] . Hsp90 modulates assembly of AS in an ATP-dependent manner by restricting conformational fluctuations [117] .
The mechanism that causes post-translational changes of AS includes phosphorylation at residue serin (Ser)129 by kinases [118] [119] [120] [121] (promoting fibril formation in vitro [122] ), C-terminal truncation and ubiquitination [123] , being a common feature in synucleinopathies [124] . In a mouse model overexpressing AS enhanced phosphatase activity reduced the phosphorylation and aggregation of AS [125] , but the mechanisms for degradation of pAS are unclear. The ubiquitin (Ub)-independent proteasome pathway or a Ub-dependent pathway after dephosphorylation have both been implicated [126] .
The association of AS with membranes affects bilayer structure, stability, and fibril formation [127] . Membrane-bound AS can aggregate spontaneously [128] , but it does not require membranes to form protofibrils and fibrils [129] , and α-helical conformation correlates inversely with fibril formation [106] . Membrane binding may, therefore, prevent AS self-association [130] abolishes the aggregation and mitigates its neurotoxic effects [133] . However, the observation of aggregated AS by and of itself does not prove that aggregation is important; all available date prove that deposition of AS occurs, not that it is causal [134] .
The mechanism of AS degradation remains unclear. Some suggest that monomeric AS can be degraded by the Ub-proteasome pathway (UPP) [135, 136] , while others found that only a small portion of soluble-cellderived intermediates as oligomers, not including monomeric AS, is targeted to the 26S proteasome for degradation [137] . By contrast, total AS concentrations increase after lysosomal inhibition [136, [138] [139] [140] .
There are distinct roles in vivo for the UPS and the ALP in the degradation of AS [141, 142] and two separate lysosomal pathwayschaperone-mediated autophagy (CMA) and macroautophagy or the endosomal-lysosomal system -may be the initiating factors in AS degradation [136, 143, 144] . Dysregulation of the autophagy pathway has been observed in the brains of PD patients and in animal models of PD [145] . Macroautophagy itself is blocked by AS via Rab1a dysregulation [146] . WT AS but not mutant forms, is degraded by CMA [138, 140, 147] , whereas all forms are degraded by macroautophagy [136, 147] .
General functions of a-synuclein
The physiological function of AS is incompletely understood. However, general consensus is that it is a multifunctional protein implied in many cellular processes that coordinates nuclear and synaptic events, neuronal plasticity [88, 95, [148] [149] [150] , modulation of synaptic transmission, vesicle fusion and recycling, synaptic integrity, neuronal differentiation and regeneration [151] . It interacts with presynaptic membranes and regulates synaptic vesicle pools [95, 152] , while others found no effect of overexpressed AS on synaptic efficacy [153] . AS has functions on lipid metabolism, signal transduction, axonal transport of synaptic vesicles [73] , microtubule and membrane and regulation of endoplasmic reticulum (ER) and Golgi vesicle trafficking [45, 154] .
Of note is that knock-out mouse models of AS have no overt phenotype, suggesting that AS is not required for neuronal development and/or that compensatory pathways exist [155] . However, absence of AS is associated with striatal dopamine (DA)-dependent dysfunction [88, 149, 156] , reduction in the reserve pool of synaptic vesicles, and defective mobilization of DA and glutamate [157] . AS is involved in vesicle and membrane trafficing, presynaptic DA recruitment [158] , and neurotransmitter release [88, [159] [160] [161] [162] [163] [189] ). The GATA transcription factor of SCA directly regulates its transcription in lock-step with the rate limiting enzymes of heme-iron metabolism [190] , but its actual role remains elusive [191, 192] .
The role of α-synuclein mutations
The most direct and compelling evidence for a functional role of AS in the pathogenesis of synucleinopathies is the causal relationship between genetic mutations and disease, and gene expression profiling of SN DA neurons gave further insight into PD pathology [193] [194] [195] [196] . Approximately 7% of all PD cases result from a monogenic cause [35, 197, 198] .
In PD, mutations in AS or multiplication of the SNCA gene encoding AS, result in a phenotype of cellular inclusions, cell death, and brain dysfunctions, and familial (f ) PD mutations influence AS assembly [199, 200] .
So far, 18 PARK loci have been described, and 10 genes have been linked to PD [35, 196, 198, [201] [202] [203] [204] [205] [206] (Figure 3 ): Autosomaldominant (ad) parkinsonism is caused by the genes encoding AS or LRRK2 (leucine-rich repeat kinase 2, dardarin/PARK 8), clinically comparable to sporadic (s) PD [207] [208] [209] , but with variable neuropathology [210, 211] , suggesting an upstream role of LRRK2 in protein aggregation [212] . Mutations in the LRRK2 gene, being the most common form of fPD in the world, cause impairment of protein degradation pathways, in particular autophagy, which can lead to accumulation of AS and unbiquitinated proteins, accumulation of oxidized proteins, inflammatory response, and increased apoptosis [213] (Figure 4 ).
While the distribution of AS levels in the cytosolic or membrane fractions is similar between the G2019S (the most prevalent LRRK2 mutation) and sPD cases, there are differences in the biochemical properties of aggregated AS in G2019S-linked PD [214] .
Parkin enconding ubiquitin carboxy-terminal hydrolase L1 (UCHL1) that ubiquitinates proteins to regulate a variety of cellular processes, linked to chromosome 6q25.2-27, causes autosomalrecessive (ar) juvenile parkinsonism (arJP) [215] , most cases showing no LBs [216] . Its mutations account for about 50% of EOPD cases [217] and are the second-most common known cause of PD [218] . They cause loss of E3 Ub ligase activity, resulting in impaired ubiquitination of substrate proteins [219] , but how mutant parkin induces pathology in fPD is not exactly known. Late onset PD and healthy controls revealed similar frequencies of genetic variants [220] . Loss-offunction mutations in the nuclear-encoded mitochondrial gene PINK1 (phosphatase and tensin homologue/PTEN-induced kinase 1) (PARK8), are associated with LB pathology [221, 222] . DJ-1 (PARK7) or ATP13A2 (PARK9), and PARK2, which encodes E ubiquitin in the UPS [223] disrupting this ligase activity and mitochondrial function [224] [225] [226] , lead to arPD, but also to sPD [198] . The characteristics and molecular biology of PARK1-18 and of other genes associated with PD have recently been summarized [196, 204] .
DJ-1 was identified as a causative gene in arEOPD in a Dutch and an Italian family [227] . DJ-1 is a multifunctional redox-sensitive protein serving as a molecular chaperone [228] , a transport regulator [229, 230] , and protecting cells against OS [231, 232] , thus leading to suppression of apoptosis [233] . DJ-1 downregulation enhances cell death by OS, ER stress, and proteasome inhibition [234] , while the localization of DJ-1 to mitochondria is associated with protective actions against some mitochondrial poisons [235] . Exogenously applied DJ-1 was shown to localize to mitochondria, the cytosol, nucleus, and microsomes [227, 231, 232] , while endogenous DJ-1, locating to presynaptic terminals of striatal axons and dendrites [236] , revealed interaction with membranes of cultured cells [237] . Furthermore, DJ-1 partly colocalizes with the synaptic marker Rab3A at synaptic terminals, which suggests interaction with membrane trafficking [238] . These and [239] [240] [241] . Parkin mediating different chains of ubiquitination [242, 243] results in loss of ubiquitination causing accumulation of misfolded proteins [244] , and plays a role in maintaining mitochondrial homeostasis [245] .
It improves mitochondrial dysfunction, alters the intrinsic threshold for cytochrome c release, regulates their remodelling, promotes their autophagy and DNA repair [224, 240, [246] [247] [248] .
PINK1, that resides at the OMM [186, 249] and is also present in the cytosol [250] , modulates mitochondrial morphogenesis, distribution, and dynamics and attenuates ROS production in SN DAergic cells [251] [252] [253] [254] (Figure 4) . However, the mechanism by which PINK1 or parkin confers neuroprotection is not clear [255] . Both causes of arPD induce mitophagy or defective oxidative phosphorylation [256, 257] , and GTPase dynamic-related protein (Drp1) is one of the targets of Parkin [258] , while PINK1 is involved in mitochondrial trafficking by forming a multiprotein complex with the GTPase Miro and the adaptive protein milton [259] . Parkin, as an Ub ligase, picks up the Miro protein from the mitochondrial membrane that is going to be degraded by the proteasome, which explains the arrested mitochondrial mobility observed in PINK1 cells, and could avoid fusion with other mitochondria or release of reactive oxygen species. Thus, these two PD-related mutations are associated with alterations of mitochondrial mobility [260] . A functional interplay of PINK1 and parkin suggests that both act in a common pathway with parkin acting downstream of and modulated by PINK1 [260] [261] [262] [263] , causing similar mitochondrial defects with decrease in ATP production and bioenergetic deficiency [256, [264] [265] [266] [267] [268] . Depletion of PINK1 affects mitochondrial metabolism, calcium homeostasis and energy metabolism [269] . The fascinating interplay of Parkin, PINK1, Drp1 and mitochondrial dysfunction has been discussed recently [34, 270] .
LRRK2, which has kinase activity, and AS have a synergistic activity on cytoskeletal elements -phosphorylation by LRRK2 or β-tubulin [271] , binding of AS to β-tubulin, and its co-localisation with microtubules -suggesting a common microtubule-polymerizing action [45, 272] .
Although regulation of mitochondrial function by the PINK1/parkin pathway [273] and the role of LRRK2 mutations associated with PD in mitochondrial dysfunction are not definitely understood, association of a small fraction of LRRK2 with mitochondria suggests its role in mediating mitochondrial functions [226, 274] and LRRK2 protein expression correlates highly with its mRNA expression [275] . These findings suggest that LRRK2-induced neurodegeneration in PD brain may, at least in part, be mediated by enhanced tubulin phosphorylation, in the presence of microtubule-associated proteins [271] . Furthermore, LRRK2 interacts with several presynaptic proteins [276] , and its depletion affects the mobility and transportation of vesicles, vesicle dynamics in the synaptic bouton, and their redistribution in pre-synaptic pools.
PD-linked LRRK2 is expressed in circulating and tissue immune cells, which may also be relevant to the susceptibility of developing PD or its progression [201] . Widespread expression of LRRK2 in human brain, particularly in brainstem, suggests its association with early-stage AS pathology in PD [277] . The exact biological function of LRRK2 remains largely unclear and how its mutations lead to neurodegeneration is not known, but protein modifications from altered phosphorylation could lead to misfolding and aggregation of the target protein [278] . Therefore, increasing Three single point mutations in AS were found to be associated with EOPD: Ala53Thr (A53T), identified in a large Italian family (Contursi) [280] and in Greek kindreds [281] [282] [283] [284] , showing both AS and tau pathology [285] , The A53T mutation was also found in diffuse DLB (DDLB) [286, 287] , while the relevance of DJ-1 mutation for DLB is not known. Ala30Pro (A30P), in a German kindred [288] , shows similarities to PD but more severe pathology [289] , and E46K or Glu46Lys [295] . Tg A53T mice develop a movement disorder with AS inclusions and loss of DAergic terminals, due to mitochondrial (mt) DNA damage [296] and mitochondrial autophagy [297] , whereas double tg mice, also expressing BS, presented a milder phenoype [298] . The subcellular distribution of AS mutations, A30P and A53T, is influenced by its phosphorylation at Ser-129 [299] , and acclerates neurodegeneration in a rat model of PD [300] . PARK4, another dominantly inherited form of fPD, is caused by duplication or triplication of parkin in the UPS [223] , resulting in the production of large amounts of WT AS. [303] [304] [305] [306] , whereas knockout of LRRK2 was protective [307] . Genome wide association studies (GWAS) have shown that SNCA is also linked to sPD [308] [309] [310] , and indicate a possible link to MSA [4] , but suggest population-specific heterogeneity of these diseases [309] . A metaanalysis revealed 10 gene sets with previously unknown association with PD that pinpoint defects in mitochondrial electron transport, glucose utilization and sensing, that occur early in disease pathogenesis, while genes controlling bioenergetics are underexpressed [311] . A GWAS study identified candidate gene regions for PD in an Ashkenazi Jewish population that are implicated in neuronal signalling and the DA pathway [312] . A recent meta-analysis of the PD GWAS consortium identified a novel PD susceptibility locus, RIT2, replicated several previously identified loci, and identified more than one risk allele within SNCA and GBA [313] .
The single-prolin AS mutant A56P and the triple-prolin mutant A30P/A56P/A76P (TP)
showed reduced propensity to form proteinase K (PK)-resistant aggregates, confirming the characterization of the mutants as prefibrillar AS variants [314] . However, only the AS species with increased aggregating propensities, human WT and A30P, triggered degeneration of nigral DAergic neurons, suggesting that fibril formation of AS promotes the progressive neuronal degeneration [314] . Expansion of Rep1, a polymorphic mixed-dinucleotide repeat in the SNAC promoter region that increases expression in both animal models [315] and humans [316] , is associated with elevated risk of sPD [317, 318] , while short Rep1 genotype is associated with reduced PD risk [319] [320] [321] [322] [323] [324] , but the effect of SNCA variants on the predisposition of PD is independent of Rep1 [325] . Variants of all 3 members of the Syn family, particularly SA and SG, affect the risk of developing DLBD [326] , and detection of a gene for familial DLB in 2q35.q36 emphasized its genetic heterogeneity [327, 328] .
Genetic research into MSA has so far been lagging behind that of related neurodegenerative diseases, such as PD, but recent studies suggest that genetic factors have a role in this disease [329] . To date the majority of genetic studies in MSA have screened candidate genes for coding mutations, including SNCA, MAPT, and other PD genes, but more recently, some association studies screening for common genetic variants in MSA have been reported, and a GWAS is currently in progress (see [330] .
α-Synuclein and neurodegeneration
The in putamen [339, 343] . This suggests that AS pathology revealed by immunohistochemistry might not be caused by AS accumulation but rather by conformational changes. Different mono-and polyclonal antibodies that bind specifically to AS have been described [344] [345] [346] [347] [348] [349] [350] [351] [352] [353] .
Recently, a monoclonal anti-AS antibody (5GA) was described that distinguishes pathological from non-diseased AS, probably due to a better accessibility during the conformational changes of the protein [354] . Expression of pAS in the brain is very low under normal conditions and is undetectable by immunohistochemical methods, but is increased in PD, DLB and AD with LB pathology [355] . It is the most prominent species of AS isolated from postmortem brains with LB disease [118] . PD shows a significant increase protein aggregates are responsible for its toxicity [387, 402] . WT BS has been suggested to protect against AS toxicity based on in vitro (inhibition and fibril formation) [110] and in vivo (reduced aggregation and LB formation)
evidence [403] . Small intermediates/soluble oligomers in the aggregation process might lead to synaptic dysfunction, and neuronal death, whereas large, insoluble deposits might function as reservoir of the bioactive oligomers [404] . The polymerization of AS from unstructured monomer to mature amyloid fibrils rich in β-sheets is a multistep process that proceeds through the formation of altered-sized oligomers and polymeres [67] . Pre-fibrillar AS variants with impaired β-structure increase neurotoxicity in PD models [390] . In PD brain, tissue transglutaminase (tTG) induced crosslinks have been identified in AS monomers, oligomers, and aggregates, suggesting an interaction between AS and tTG [405] , while Hsp 70 modulates extracellular AS oligomers and rescues trans-synaptic toxicity [406] . Ferric iron may catalyse the formation of AS oligomers [407] [408] [409] , and exposure of AS to oxidative agents also induces formation of highorder oligomers [410] . Missense mutations of SNCA, e.g. A30P, increase oligomerization of AS, but not fibril formation [77, 411] .
Spheroidal oligomers contain a significant amount of α-helical structure, which decreases in protofilaments, while β-sheet structure content of AS increases from spheroid oligomers, through protofibrils, to fibrils [412] .
Methods to detect morphologically distinct oligomeric forms of AS have been described [413] . Elevated levels of soluble AS oligomers were found in post-mortem extracts of PD [414] and DLB brains [415, 416] . Loss of DAergic nigral cells in animals with AS variants that form oligomers (E57K, E35K) showed that these are toxic in vivo and might disrupt membranes [417] . DA and its metabolites inhibit the conversion of protofibrils to fibrils and may promote protofibril accumulation [418] .
Intervention in the early part of the aggregation pathway by prevention of oligomer formation or increased clearance may be neuroprotective [419, 420] .
Oligomeric species can be isolated from cells [139, 421, 422] , from human [423] and mouse brain [424] , particulary found in membraneenriched fractions [128, 414] . causing energy depletion [471, 472] , which is relevant given the importance of mitochondria in maintaining neuronal viability [473, 474] .
Overexpression of AS impairs mitochondrial complex I function, decreasing respiration and increasing free radical production [82, 338, 472, 475, 476] or complex IV activity [296] . Complex-I is inhibited in DA-neurons by systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) [477] , probably linked to mtDNA defects [478] . but its activity is not impaired in other neurodegenerative diseases [479] . AS apparently can interact with complex-I, resulting in its reduced mitochondrial activity, increased free radical production, and mitophagy [475] .
Impaired complex-I mitochondrial biogenesis has been found in PD frontal cortex [480] . AS may bind to mitochondrial membranes leading to mitochondrial fragmentation followed by loss of mitochondrial transmembrane potential and neuronal death [225, 472] . This, however, AS depletion enhances this pathway [146] .
Increases in macroautophagy lead to decreases in AS load and improvements of neuronal function [136, 487] , while its inhibition protects against toxic effects of AS. This indicates that macroautophagy can be harmful rather than protective [488, 489] . Aberrant AS can bind to the membranes of lysosomes, inhibiting CMA [138, 187, 490] , lysosomal function [445, 446] , and the proteasome [137,335,336,436,445- whereas inhibition of glucocerebrosides had no effect on AS levels [502] . There are also genetic and pathological links between PD and the lysosomal disorder Sanfilippo syndrome [503] . GBA mutations -more than 28 of which are presently recognized [504] -are the most frequent genetic risk factor for PD [505, 506] , particularly in fPD [507] , and glucocerebrosidase is present in AS inclusions in LB disorders [494] . Peroxynitrite, formed by reduced superoxide dismutase (SOD), induces aggregation of AS in situ, and nitrated AS is found in the core of LBs [512] . Cross-linking of AS by AGEs may reflect early disease-specific changes, accelerating inclusion body formation [528] . Formation of AS protofibrils is stimulated by translational modifications that occur under conditions of OS, while its aggreation is inhibited by antióxidants and proteins with chaperone activity [529] . These findings in human PD and models indicate a multicomponent process in its pathogenesis, and cell death pathways are caused by many interacting factors [530, 531] (see Figures 4 and 6) .
α-Synuclein and neuroinflammation
AS can trigger inflammation and activation of microglia [532, 533] , which, by releasing toxic factors or by phagocytosing cells, and degrading AS more avidly than neurons or astrocytes [534] , may form a selfperpetuating cycle for neurodegeneration [535] [536] [537] . This inflammatory response may occur after neuronal death, but it is also possible that AS is released via exocytosis [534] or even that cleaved portions are presented via antigene presentation, which could lead to a vicious cycle of inflammatory response, release of (modified) AS, and further inflammation.
In PD, SN cell degeneration is associated with astroglial reaction and HMC class II positive microglia that may be both inducing factors or sequelae of neuronal death [545] [546] [547] , while oligodendroglia does not seem to play a role in promoting inflammation, although they may be damaged by it [533] . 
α-Synuclein and protein interactions
Despite clinical, genetic, and neuropathological differences, there is considerable overlap Figure 6 . Role of α-synuclein (AS) in neurodegeneration in PD. Neurotoxic oligomers of α-synuclein are the key factors of neurodegeneration. One potential mechanism leading to neuronal death is invasion of α-tubulin oligomers which affects the dynamics of microtubules (modified after [398] [569] . Independent and joint effects of the SNCA and MAPT (tau) genes in PD have been described [570, 571] , and the MAPT H1 haplotype has been reported to be a risk factor for PD [572] , while it reduces the severity of AD pathology [573] . Polymorphisms between SNCA and MAPT interact to influence the rate of progression of PD, which is more prominent in the early stages of the disease [574] . Recent GWAS show that polymorphism in the MAPT and SNCA genes confers a 25.6%
increased risk factor for PD [308, 571, 575] .
Whereas AS can spontaneously polymerize into amyloidogenic fibrils in vitro, tau polymerization requires an inducing agent, e.g. AS seeds [121] .
Cellular, various tg and other experimental PD models provided new insight in the hyperphosphorylation of tau [566, 569, [576] [577] [578] [579] [580] . They suggest that oxidatively modified AS is degraded by the proteasome and plays a pro-aggretatory role for tau [581] , and that AS is an in vivo regulator for tau phosphorylation at Ser 262 leading to deposition of both proteins [582] . Oxidatively modified AS degraded by the proteasome further promotes the recruitment of tau to protein inclusions in oligodendroglial cells in synucleinopathies [581] . E46K modification of AS may induce tau inclusions both direct and indirect mechanisms being involved in the formation of protein inclusions [583] . On the other hand, tau enhances AS aggregation and toxicity and disrupts AS inclusion formation in cellular models [584] . Recent postmortem studies showed increased accumulation of p-tau in the striata of PD patients and in the A53T mutant mouse model [343, 577] , related to increased activity of GSK-3β [566, 579] . This is stimulated by AS that associates with the actin cytoskeleton [585] and by GSK-3β [568] . DA D1 receptor activation induces tau phosphorylation via cyclin-dependent kinase 5 (cdk5) and GSK-3β signalling pathways [586] . Thus, tauopathy in PD may have a restricted pattern of distribution [578] , which differs from its generalized affection in AD.
There is a strong interaction between AS, tau and β-amyloid (Aβ), particularly in their oligomeric forms, which might synergistically promote their mutual aggreation et vice versa [68, 165, 582, 587] . Cross-seeding beween dissimilar proteins that share β-sheet structures has been described, for example for tau and AS [588] . In vivo interactions between AS and tau are supported by genetic studies that link MAPT gene, which encodes tau, with increased risk for sPD [309, 589, 590] , and in fPD, fibrillation of AS and tau is caused by the A53T mutation [588] .
Tau phosphorylation was found in synapseenriched fractions of frontal cortex in PD and AD [355] and in brainstem of AS mice [591] and EO familial DLB shows extensive tau pathology [592] . 
a-Syunclein spread and disease propagation
Mounting evidence implicates that templated corruption of disease-specific proteins and their promotion may be a mechanism of disease propagation in neurodegenerative disorders by transneuronal spread through neural networks [608] . The concept that AS lesions ramify within the CNS by a seeding-like process is supported by the observation that fetal DA transplants in the striatum in a subset of PD patients surviving more than 5 years may develop AS-positive LBs [609] [610] [611] . These data imply for a host-to-graft propagation, and a neuron-to-neuron (interneuron) transmission or transsynaptic spread of AS appears important for the propagation of the disease.
Similar accumulation of AS occurs in stem cells
transplanted to tg mice [612] . Development of
LBs in transplanted DAergic neurons has been
suggested to develop similar to that in the host SN [613] , but it could not be determined whether the LB-like inclusions were formed by the spread of AS fibrils, or due to some other toxic effect of the neighbouring diseased neurons [60] . Since the transplants were derived from multiple, genetically unrelated sponsors, it seems likely that the inclusions were a consequence of factors inherent in the PD brain. Likewise, aberrant tau has been proposed to be secreted from cells via exosomal release early in the AD disease process [622] , and trans-synaptic spread of tau pathology is seen in vivo [626] .
Prions are composed solely of PrP Thus, the propagation of AS lesions by cellto-cell passage appears to be similar as that in other neurodegenerative disorders (see [9, 626] [429] [430] [431] 636] . The formation of axonal AS deposits and "pale bodies" [637] preceds the development of LBs in affected neurons. Loosely packed AS filaments as earliest or premature "pale neurites" are initiated at axon collaterals and extend centripetally into proximal segments [638] . (Table 2) . Recent studies revealed cell-specific sequestration of choline acetyltransferase (CAT) and TH within LBs, suggesting that LBs may disrupt cholinergic and catecholaminergic neurotransmitter production by sequestration of the rate-limiting enzymes for their synthesis [648] . Recent demonstration of the autophagy adapter protein NBR1, which interacts with Ub via the Ub-associated (UBA) domain for degradation of ubiquitinated substrates in a way similar to p62 [649] , suggests that NBR1
Formation and development of AS/Lewy pathology
is involved in the formation of cytoplasmic inclusions in α-synucleinopathies [650] . AS can be recovered from purified LBs from PD and DLB brain [651] , and recumbinant AS tends to form LB-like fibrillar structures in vitro [652] . Redox-active iron Vesicular monoamine transporter 2 (VMAT2) LC3, GABARAP and GATE-16 (autophagosomal proteins) [646] Histone deacetylase 6 (aggresome-related protein) [647] were identified [595] , whereas another study identified 1263 proteins in SN [653] . final degradation by astroglial processes [640] .
LBs are accompanied by dystrophic neurites, which according to recent 3-dimensional studies may evolve into LBs, with Ub at the core and neurofilaments at the outermost layer [655] . LB pathology [340, 429, [663] [664] [665] . Longitudinal clinico-pathologic studies showed that 17-31%
Relationship between α-synuclein and Lewy pathology
of PD patients have a fast disease progression [666, 667] .
A recently proposed unifying system for LB diseases correlates AS pathology with nigrostriatal degeneration, cognitive impairment, and motor dysfunctions [660] .
Whereas the old classification left 45-50% of individuals unclassified [668, 669] , all were now classified into 1 of 4 stages (Figure 8 ). This is supported by an increase of pAS restricted to the olfactory bulb and brainstem in early stages of LB pathology [634] . Progression through There is no "gold standard" for the pathological diagnosis of DLB and PDD. Their hallmark is AS pathology manifested as LBs or a variable mixture of AS and AD pathologies, which may interact synergistically [690] [691] [692] . Both cortical and subcortical AS pathologies have been suggested to be the main determinant [693, 694] , whereas others suggested AD pathology to be more important, particularly when the Aβ load may be similar to that in AD [695] . The severity and extent of AS are variable, and according to revised guidelines are scored semiquantitatively in specific brain areas [593, [696] [697] [698] [699] . AD pathology is a consistent but not universal finding in both disorders, differentiating two types of DLB: The "common form" is characterized by abundant neocortical senile plaques and NFTs in the limbic cortex; while "pure DLB" shows minimal AD lesions [700] . NFTs, being frequent in both DLB and PDD, are often restricted to limbic regions, whereas excessive tau pathology may be absent [687] . Beween 10 and 50% of PDD cases had enough AD lesions to attain the pathological diagnosis of definite AD using CERAD criteria [92, [701] [702] [703] [704] , but PDD may also develop in the absence of significant AD pathology, related to higher Braak LB stages [702] . Reduced cortical cholinergic innervation in DLB and PDD is similar and lower than in AD [705, 706] . Synaptic loss is a consistent feature in DLB and is of equal severity as in AD [707] .
Despite many similarities between DLB and PDD, several morphological differences have been demonstrated, in particular higher amyloid plaque load in striatum, usually absent in non-demented PD [37, 38, 630, 708] , and more severe AS load in hippocampal CA2/3 areas [429] [430] [431] . A recent study showed DLB cases having more severe Aβ load than PDD, but no differences in neuritic Braak and AS scores, while others found higher Aβ scores in cortical and subcortical areas [692] . Other differences between PDD and DLB are more [720] ; showing AS in these structures [721] . NCIs show a meshwork of granule-associated filaments 18-28nm in diameter, similar to those of oligodendroglia [722] . Involvement of the autonomous nervous system leads to clinical autonomic disturbance [717, 723] . It was discussed whether myelin loss in many networks is a primary event in MSA or due to neuronal depletion [724] .
Biochemical studies showed increased insolubility of AS even in brain areas with few GCIs, indicating that AS aggregation precedes the formation of inclusions [21, 346] .
Immunoblotting of brain extracts showed 19kDa species with higher molecular weight bands, representing aggregated protein [346] , and a newly described specific antibody (5GA) detects AS deposits with much higher sensitivity [354] . GCIs contain modified AS nitrated and phosphorylated at Ser 129, which has an enhanced ability to form fibrils, while nitration may indicate a role of oxidative damage [122, 521, 725] . In addition to AS, GCIs and NCIs contain a large number of proteins, oligodendroglial markers, myelin basic protein (MBP), as well as p25α tubulin-polymerizationpromoting protein (TPPP) [726, 727] ; which promotes AS phosphorylation [728] and shows interaction with MBP (see [13, 729] ) (Table 3 ).
The 
animal models of parkinson's disease
In an attempt to shade light on the neurobiology of PD, numerous experimental models have been developed. They come from essentially 3 sources: pharmacological, e.g. reserpine, toxic e.g. MPTP [738] , rotenone and paraquat [739] [740] [741] [742] , and genetic. Despite [748] [749] [750] , Caenorhabditis elegans [492, 751] and in mammalians [752] have been developed to study the cellular mechanisms impaired in this disease [746] .
Although some genetic models reproduced the key features of PD, most of them induced DA neurodegeneration, but did not succeed in reproducing both the broad pathology and progressive degenerating process in human PD [747, 753, 754] . To date, viral PD models comprise AS and LRRK2-based overexpression or mimic parkin loss of function by overexpression of parkin substrates [755] . These viral and other recent genetic models models are hoped to provide valuable insights into PD mechanisms in order to contribute to the development of Table 3 . List of protein constituents identified in glial cytoplasmic inclusions (GCIs) from human multiple system atrophy brain (modified from [729] ).
MS+: polypeptides identified by mass spectrometry following affinity purification of glial cytoplasmic inclusion body purification as described in [730] [731] [732] a : Known oligodendroglial markers 
α-Synuclein as a biomarker for synucleinopathies
Numerous forms of AS can be released into cerebrospinal fluid (CSF) and other biological fluids of healthy subjects and patients with neurodegenerative disorders [760] and is also abundantly expressed in the hematopoetic system [190] . Full-length AS has been recovered from lumbar CSF in PD and DLB patients [731, 761] . As a candidate biomarker of synucleinopathies, namely PD and DLB, AS determination in CSF [762] was hoped to improve the clinical diagnostic accuracy.
Although AS is the main constitutent of LBs, the detection of AS in body fluids of patients with synucleinopathies has yielded promising but inconsistent results [763,764,764a] . Similar to divergent results on the plasma levels of AS in PD [765] [766] [767] , retrospective studies of CSF provided inconclusive and contradictory results [731, 760, [768] [769] [770] [771] . pAS was detected in PD samples, which was not the case for oligoAS or oligo-pAS [772] . Confirming several studies showing relatively low CSF AS concentrations in both PD and DLB [731, [773] [774] [775] , more recent ones reported significantly lower AS levels in PD [776, 777] as well as in PD, DLB and MSA than in AD [777] [778] [779] . While CSF levels of AS oligomers were significantly increased in PD patients against controls [298, 416, 780] , AD and progressive supranuclear palsy (PSP) [781] , others were unanble to detect oligomeric AS in CSF [776] . Recent work detected alterations in AS phosphorylation (Ser129) in the CSF of PD patients [782] .
However, CSF AS alone did not provide relevant information for PD diagnosis, showing low specificity, but a better performance was obtained with the total tau/AS ratio, giving a sensitivity of 89% and specificity of 61%, contributing to the determination of PD [777] .
A recent study reported different levels of CSF biomarkers in different phenotypes of PD, non-tremor-dominant (NT-PD) patients
showing significantly higher levels of CSF tau and index tau/Aβ than early onset and tremor-dominant PD and controls, but no differences between NT-PD and AD [783] .
These data were confirmed by personal studies [9] , corroborating the opinion that CSF levels of tau may be a biomarker for the presence and severity of neurodegeneration [784, 785] , while others did not see such biomarker changes [786] [787] [788] . Other recent studies showed that CSF AS is currently unsuitable to differentiate between PD and atypical parkinsonism [789] . The source of PDlinked AS in human CSF remains unknown, but recent studies suggest that despite the higher levels in peripheral blood products, neurons in the CNS represent the principal source of AS in human CSF [790] . Postmortem CSF levels of oligomeric AS and pAS significantly raised in MSA compared to other controls and other synucleinopaties, but did not distinguish PD and DLB from PSP or control groups [791] . CSF AS levels did not differ significantly between DLB and/or PD and AD [792] , but AS levels were reduced in DLB patients with long disease duration or worse cognitive performance [760, 792] . DLB compared with PD, PDD, and AD showed the lowest CSF levels of Aβ42 and, when combined with CSF tau, differentiated DLB from PD and PDD; but not from AD [788] , and PiB PET binding showed higher amyloid loaden in DLB and AD than in PD, PDD and controls [793, 794] . While earlier studies showed increased CSF total (t)tau in both DLB and AD [795] , others found differences for both t-tau and p-tau differentiating DLB from AD [796] , and levels of t-tau and p-tau181
were significantly increased in DLB [797] . and a specificity of 90% [802] . In autopsyconfirmed cases of DLB and AD, p-tau 181
yielded only a sensitivity of 75%, and specificity of 61%, with diagnostic accuracy of 73% [803] .
According to recent studies, reduction of dihydroxyphenylacetic acid was seen in both early PD and MSA, separating recent onset PD from controls with 100% sensitivity and 89%
specificity, but was of no value in differing PD from MSA [804] . and the combined approach may be the most promising way for the identification of (imaging and protein) biomarkers [806] .
conclusions and final remarks
AS is a small, soluble neuronal protein with predominantly presynaptic location in brain as well as in many other organs. aiming to achieve disease modification [812] .
These developments and the development of new targets or novel candidate drugs that might be neuroprotective for PD and other proteinopathies are major challenges of modern neurosciences.
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